VASCULAR ENDOTHELIAL GROWTH FACTOR C AND VASCULAR ENDOTHELIAL GROWTH FACTOR D BIOLOGY FUNCTIONS AND...
Tìm thấy 10,000 tài liệu liên quan tới từ khóa "VASCULAR ENDOTHELIAL GROWTH FACTOR C AND VASCULAR ENDOTHELIAL GROWTH FACTOR D BIOLOGY FUNCTIONS AND...":
Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer
Gefitinib, an EGFR-tyrosine kinase inhibitor, significantly improve prognosis in patients with advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the usefulness of MUC1 and vascular endothelial growth factor (VEGF) mRNA expression in peripheral blood as means of predi[r]
BÁO CÁO HÓA HỌC VASCULAR ENDOTHELIAL GROWTH FACTOR A AND CHEMOKINE LIGAND CCL2 GENES ARE UPREGULATED IN PERIPHERAL BLOOD MONONUCLEAR CELLS IN INDIAN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS POT
ALS, amyotrophic lateral sclerosis; VEGF-A, vascular endothelial growth factor-A; CCL2, chemokine ligand-2; PBMCs, peripheral blood mononuclear cells.. Guptaet al.Journal of Neuroinflamm[r]
6 Đọc thêm
Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity
Specifically, patients with GC were shown to have en- hanced levels of vWF:Ag and vWF activity in plasma and a strong correlation was observed between these two variables and disease severity. These findings are similar to previous data from patients with colorectal ca[r]
Pleural fluid osteopontin, vascular endothelial growth factor, and urokinasetype plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with
Although the uPA concentration is elevated in the MPE, the more substantially elevated concentrations of its inhibitors, namely PAI-1 and PAI-2, likely result in depressed fibrinolytic activity and favor the deposition and maintenance of intra-pleural fibrin. Peder[r]
INTERPLAY BETWEEN 3′-UTR POLYMORPHISMS IN THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENE AND METABOLIC SYNDROME IN DETERMINING THE RISK OF COLORECTAL CANCER IN KOREANS
Polymorphisms in angiogenesis-related genes and metabolic syndrome (MetS) risk factors play important roles in cancer development. Moreover, recent studies have reported associations between a number of 3′-UTR polymorphisms and a variety of cancers.
PREDICTING RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR AND CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER
Bevacizumab improves progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer patients however currently there are no biomarkers that predict response to this treatment. The aim of this study was to assess if differential protein expression can differentiate patients[r]
BÁO CÁO HÓA HỌC:" VASCULAR ENDOTHELIAL GROWTH FACTOR REGULATES MELANOMA CELL ADHESION AND GROWTH IN THE BONE MARROW " POT
Western Immunoblot Analyses
To study COX-2 expression by cultured B16M, basal medium-cultured B16M cells were treated or not for 4 h with 10 and 100 ng/ml recombinant murine VEGF. Then, they were collected in the lysis buffer [300 mM NaCl, 50 mM HEPES, 8 mM EDTA, 1% NP40, 10% gly-[r]
14 Đọc thêm
TÀI LIỆU BÁO CÁO KHOA HỌC: BRAIN ANGIOGENESIS IN DEVELOPMENTAL AND PATHOLOGICAL PROCESSES: THERAPEUTIC ASPECTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR DOC
Other brain tumors
In other brain tumors, hemangioblastoma is relatively rare ( 3% of all tumors in the CNS), but occurs in von Hippel–Lindau (VHL) patients. This tumor occurs not in the cerebrum, but in limited areas such as the retina, cerebellum, brainstem
In other brain tumors, hemangioblastoma is relatively rare ( 3% of all tumors in the CNS), but occurs in von Hippel–Lindau (VHL) patients. This tumor occurs not in the cerebrum, but in limited areas such as the retina, cerebellum, brainstem
Xem Thêm " IMPACT OF OXIDATIVE STRESS ON THE BLOOD RETINAL BARRIER "
Xem Thêm " COALESCENCE IN A SINGLET DOUBLET SYSTEM AT QUASIEQUILIBRIUM "
8 Đọc thêm
BÁO CÁO SINH HỌC VASCULAR ENDOTHELIAL GROWTH FACTOR REGULATES MELANOMA CELL ADHESION AND GROWTH IN THE BONE MARROW PPT
Results:Mice given one single intravenous injection of LPS 6 hour prior to cancer cells significantly increased B16M metastasis in BM compared to untreated mice; however, administration [r]
14 Đọc thêm
A PHASE II STUDY OF ENDOSTATIN IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND RADIOTHERAPY IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
Endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular endothelial growth factor in different human cancers. This study assessed the efficacy of endostatin combined with concurrent chemoradiotherapy of non-small cell lung cancer (NSCLC).
THE IMMUNE-CHECKPOINT HLA-G/ILT4 IS INVOLVED IN THE REGULATION OF VEGF EXPRESSION IN CLEAR CELL RENAL CELL CARCINOMA
Clear cell renal cell carcinoma (ccRCC), the most aggressive renal cancer, is characterized by early lymph node metastases and bad prognosis. Most therapies targeting advanced or metastatic ccRCC are based, as first-line treatment, on the administration of the vascular endothelial growth factor (VEG[r]
INCREASED WNT5A IN SQUAMOUS CELL LUNG CARCINOMA INHIBITS ENDOTHELIAL CELL MOTILITY
Angiogenesis is important both in normal tissue function and disease and represents a key target in lung cancer (LC) therapy. Unfortunately, the two main subtypes of non-small-cell lung cancers (NSCLC) namely, adenocarcinoma (AC) and squamous cell carcinoma (SCC) respond differently to anti-angiogen[r]
SUNITINIB-INDUCED SEVERE TOXICITIES IN A JAPANESE PATIENT WITH THE ABCG2 421 AA GENOTYPE
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that acts against receptors for vascular endothelial growth factor and platelet-derived growth factor. Common toxicities of sunitinib treatment include hypertension, hand–foot syndrome, vomiting, and diarrhea, and the proportion of gra[r]
(SECONDARY) SOLID TUMORS IN THYROID CANCER PATIENTS TREATED WITH THE MULTI-KINASE INHIBITOR SORAFENIB MAY PRESENT DIAGNOSTIC CHALLENGES
Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors.
PHASE II STUDY OF AXITINIB WITH DOUBLET CHEMOTHERAPY IN PATIENTS WITH ADVANCED SQUAMOUS NON–SMALL-CELL LUNG CANCER
Axitinib is an orally active and potent tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-naïve patients with advanced/metastatic (stage IIIB/IV) s[r]
10 Đọc thêm
COMBINED APPLICATION OF ANTI-VEGF AND ANTI-EGFR ATTENUATES THE GROWTH AND ANGIOGENESIS OF COLORECTAL CANCER MAINLY THROUGH SUPPRESSING AKT AND ERK SIGNALING IN MICE MODEL
Angiogenesis is generally involved during the cancer development and hematogenous metastasis. Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) are considered to have an important role in tumor-associated angiogenesis. However, the effects of simultaneously target[r]
PHASE I DOSE-ESCALATION STUDY OF PAZOPANIB COMBINED WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA OR OTHER ADVANCED TUMORS
Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal antibody have been re[r]
APATINIB TREATMENT FOR KIT- AND KDR-AMPLIFIED ANGIOSARCOMA: A CASE REPORT
Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gastric cancer.
IMPAIRMENT OF COGNITIVE FUNCTIONING DURING SUNITINIB OR SORAFENIB TREATMENT IN CANCER PATIENTS: A CROSS SECTIONAL STUDY
Impairment of cognitive functioning has been reported in several studies in patients treated with chemotherapy. So far, no studies have been published on the effects of the vascular endothelial growth factor receptor (VEGFR) inhibitors on cognitive functioning.
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of apatinib in patients with non-triple-negative metastatic breast cancer who had received prior chemotherapy for their metastatic dise[r]